Previous studies have found that higher CD33 expression in the parietal lobe is associated with more advanced cognitive decline or disease status [21], and knocking out CD33 results in lower Aβ levels and reduced amyloid plaque burden in the brain [6]. The gene discussed is CD33; the disease is Mental deterioration.